Erlotinib in previously treated non-small-cell lung cancer.

  title={Erlotinib in previously treated non-small-cell lung cancer.},
  author={Frances A. Shepherd and J Rodrigues Pereira and Tudor Eliade Ciuleanu and Eng Huat Tan and Vera Hirsh and Sumitra Thongprasert and Daniel Campos and Savitree Maoleekoonpiroj and Michael Smylie and Renato G. Martins and Maximiliano van Kooten and Mircea Dediu and Brian P. Findlay and Dongsheng Tu and Dianne B. Johnston and Andrea Bezjak and Gary M. Clark and P. Moreno Santabarbara and Lesley Seymour},
  journal={The New England journal of medicine},
  volume={353 2},
BACKGROUND We conducted a randomized, placebo-controlled, double-blind trial to determine whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival in non-small-cell lung cancer after the failure of first-line or second-line chemotherapy. METHODS Patients with stage IIIB or IV non-small-cell lung cancer, with performance status from 0 to 3, were eligible if they had received one or two prior chemotherapy regimens. The patients were stratified according to center… 

Figures and Tables from this paper

A Phase II Study of Erlotinib in Patients with Previously Treated Non-Small Cell Lung Cancer

Elotinib was found to be effective for Japanese patients with previously treated NSCLC in clinical practice and common adverse events were tolerable skin toxicities, diarrhea, and stomatitis.

Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer.

  • B. BesseN. Leighl B. Johnson
  • Medicine, Biology
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2014
Everolimus 5 mg/ day plus erlotinib 150 mg/day was not considered sufficiently efficacious per the predefined study criteria and the combination does not warrant further investigation based on increased toxicity and the lack of substantial improvement in disease stabilization.

Erlotinib as maintenance therapy in patients with advanced non-small cell lung cancer: a pooled analysis of three randomized trials

The addition of maintenance erlotinib significantly improves PFS and OS in patients with advanced non-small cell lung cancer who had not progressed after four cycles of first-line chemotherapy.

Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer.

  • N. HannaR. Lilenbaum P. Bonomi
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2006
Although the response rate with single-agent cetuximab in this heavily pretreated patient population with advanced NSCLC was only 4.5%, the disease control rates and overall survival seem comparable to that of pemetrexed, docetaxel, and erlotinib in similar groups of patients.

Erlotinib monotherapy in patients with advanced non-small cell lung cancer: an effective approach with low toxicity.

Erlotinib is effective and well tolerated in pretreated patients with advanced NSCLC and a good performance status and its impact on survival is assessed.

Pemetrexed versus Gefitinib versus Erlotinib in Previously Treated Patients with Non-Small Cell Lung Cancer

Both oral epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) had comparable efficacy and safety and the superior PFS and OS of EGFR TkIs with more favorable baseline clinical characteristics than those of pemetrexed suggest the impact of baseline clinicopathological factors.

A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC).

The addition of sunitinib to erlotinib did not significantly improve PFS in patients with advanced, platinum-pretreated NSCLC and was fairly well tolerated although most treatment-related adverse events (AEs) were more frequent.



Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.

Erlotinib was active and well tolerated in this patient population, and further clinical development is clearly warranted; cutaneous rash seems to be a surrogate marker of clinical benefit, but this finding should be confirmed in ongoing and future studies.

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

  • M. FukuokaS. Yano J. Baselga
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2003
Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in patients with pretreated advanced non-small-cell lung cancer.

Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens

Patients who received docetaxel had a longer time to progression and a greater progression-free survival at 26 weeks and the 1-year survival was significantly greater with D75 than with the control treat...

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

Treatment with docetaxel is associated with significant prolongation of survival, and at a dose of 75 mg/m(2), the benefits of docetAXel therapy outweigh the risks.

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

Gefitinib in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced NSCLC did not have improved efficacy over gemcitABine and cascplatin alone, and the reasons for this remain obscure and require further preclinical testing.

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

Gefitinib, a well-tolerated oral EGFR-tyrosine kinase inhibitor, improved disease-related symptoms and induced radiographic tumor regressions in patients with NSCLC persisting after chemotherapy.

Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome?

Analysis of phase II trials of erlotinib (Tarceva) in non-small-cell lung cancer, head and neck cancer, and ovarian cancer shows a significant association between rash severity and objective tumor response, suggesting that rash may serve as a marker of response to erlot inib treatment and may be used to guide treatment to obtain optimal response.

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

  • V. MillerM. Kris R. Heelan
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2004
The data suggest that individuals in whom gefitinib is efficacious are more likely to have adenocarcinomas of the bronchioloalveolar subtype and to be never smokers, and suggest that NSCLC has a different biology in patients who never smoked and those with bronchiola alveolar carcinoma.

Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials

The results of this meta-analysis suggest that chemotherapy may have a role in treating non-small cell lung cancer, and reached conventional levels of significance when used with radical radiotherapy and with supportive care.